Nuformix plc
Nuformix plc (NFX.L) Company Profile & Overview
Explore Nuformix plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Nuformix plc (NFX.L) Company Profile & Overview
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.